Ascendis Pharma A/S (ASND)

FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing

Ascendis to Share Latest Advances in Hypoparathyroidism and Achondroplasia Programs at ASBMR 2026

Ascendis Pharma A/S’s (ASND) “Overweight” Rating Reaffirmed at Cantor Fitzgerald

Ascendis Pharma: Back To Full Independence

Ascendis Pharma A/S (ASND) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Why Is Ascendis Pharma Stock Trading Lower on Tuesday?

Ascendis to Regain Rights to TransCon® Technology in Metabolic and Cardiovascular Diseases

Ascendis Announces Planned $400 Million Share Repurchase Program

Head-To-Head Analysis: Ascendis Pharma A/S (NASDAQ:ASND) versus MeiraGTx (NASDAQ:MGTX)

First Infant Data from Ascendis Trial of Once-Weekly TransCon CNP (Navepegritide) Presented at ESPE 2026

Ascendis Pharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE 2026

Ascendis Pharma, Science Applications International And Other Big Stocks Moving Higher On Monday

Biomarin, Ascendis Reach Mutually Beneficial Agreement Ending Global Patent Disputes

Ascendis and BioMarin Enter Binding Term Sheet for a Global Settlement and License Agreement Related to YUVIWEL® (Navepegritide)

This Ascendis Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday

Ascendis Announces Oral Presentation of Week 104 Data from Its Pivotal Trial of TransCon® CNP (Navepegritide) at ISDS 2026

Eyconis Announces Initiation of First-in-Human Clinical Trial of EYC-0305 in Treatment-Naïve Wet Age-Related Macular Degeneration Patients

Ascendis Pharma A/S (ASND) Q2 2026 Earnings Call Transcript

Ascendis Pharma A/S Q2 Earnings Call Highlights